Advertisement

Protein Biomarkers in the Management of Hepatocellular Carcinoma: Novel Combinatory Approaches

  • Philip JohnsonEmail author
  • Sarah Berhane
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Several serum biomarkers have been proposed for diagnosis and assessment of prognosis in hepatocellular carcinoma (HCC) but none has entered routine clinical practice despite achieving reasonably high values for sensitivity, specificity and area under the ROC curve. After reviewing some of these we show how the performance of individual biomarkers may be enhanced by combining several different biomarkers in rigorously developed and validated statistical models. In such models the constituent biomarkers are considered as continuous variables rather than, as in conventional clinical practice, dichotomised with the application of cut-off points. This approach maximises the information extracted from the available data. We illustrate this concept with reference to the ‘GALAD’ model for diagnosis and the ‘BALAD’ model for prognosis both of which improve the utility of the individual constituent biomarkers.

Keywords

Chronic Liver Disease Sustained Virological Response Lens Culinaris Agglutinin Indocyanine Green Clearance Assess Liver Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Abelev G, Perova S, Khramkova N, Postnikova Z, Irlin I. Production of embryonal [alpha]-globulin by transplantable mouse hepatomas. Transplantation. 1963;1:174–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat Med. 2004;23:1159–78.CrossRefPubMedGoogle Scholar
  3. 3.
    Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008;8:200.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P. Diagnosis and prognostication in hepatocellular carcinoma: application of the GALAD and BALAD-2 serology models. Clin Gastroenterol Hepatol. 2016 Jan 13. PII: S1542-3565(16)00044-6. DOI: 10.1016/J.CGH.2015.12.042. [EPUB ahead of print]
  5. 5.
    Bertino G, Neri S, Bruno C, Ardiri A, Calvagno G, Malaguarnera M, Toro A, Clementi S, Bertino N, di Carlo I. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 2011;102:363–71.PubMedGoogle Scholar
  6. 6.
    Bertino G, Ardiri A, Malaguarnera M, Malaguarner G, Bertino N, Calvagno GS. Hepatocellular carcinoma serum markers. In: Seminars in oncology. Amsterdam: Elsevier; 2012. p. 410–33.Google Scholar
  7. 7.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191–207.CrossRefPubMedGoogle Scholar
  9. 9.
    Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Chan SL, Mo F, Johnson P, Li L, Tang N, Loong H, Chan AW, Koh J, Chan AT, Yeo W. Applicability of BALAD score in prognostication of hepatitis B‐related hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30(10):1529–35.Google Scholar
  12. 12.
    Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.PubMedGoogle Scholar
  13. 13.
    D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.CrossRefPubMedGoogle Scholar
  14. 14.
    del Priore G, Zandieh P, Lee M-J. Treatment of continuous data as categoric variables in obstetrics and gynecology. Obstet Gynecol. 1997;89:351–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87:121–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013;280:2471–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Forner A, Reig M, Bruix J. α-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology. 2009;137:26–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Fox R, Berhane S, Teng M, Cox T, Tada T, Toyoda H, Kumada T, Kagebayashi C, Satomura S, Johnson P. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer. 2014;110:2090–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Fuzery A, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10:13.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gao P, Li M, Tian Q, Liu D. Diagnostic performance of des-γ-carboxy prothrombin (DCP) for hepatocellular carcinoma: a bivariate meta-analysis. Neoplasma. 2011;59:150–9.CrossRefGoogle Scholar
  21. 21.
    Hadziyannis E, Sialevris K, Georgiou A, Koskinas J. Analysis of serum α-fetoprotein-L3 % and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels. Oncol Rep. 2013;29:835–9.PubMedGoogle Scholar
  22. 22.
    Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, Amano Y, Kinoshita Y. Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol. 2011;26:739–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Hann H-W, Li D, Yamada H, Satomura S, Coben R, Dimarino AJ. Usefulness of highly sensitive AFP-L3 and DCP in surveillance for hepatocellular carcinoma in patients with a normal alpha-fetoprotein. J Med Microb Diagn. 2014;3(2161–0703):1000130.Google Scholar
  24. 24.
    Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the albi grade. J Clin Oncol JCO. 2014;2014(57):9151.Google Scholar
  25. 25.
    Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23:144–53.CrossRefPubMedGoogle Scholar
  26. 26.
    Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo K-J, Lee S-D, Coleman MS, Furie B. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. New Engl J Med. 1984;310:1427–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Liu X-F, Hu Z-D, Liu X-C, Cao Y, Ding C-M, Hu C-J. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Biochem. 2014;47:196–200.CrossRefPubMedGoogle Scholar
  30. 30.
    Liu J, Zuo X, Wang S. Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2015;19:3655–73.PubMedGoogle Scholar
  31. 31.
    Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59:1687–93.CrossRefPubMedGoogle Scholar
  32. 32.
    Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110–8.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Mossad NA, Mahmoud EH, Osman EA, Mahmoud SH, Shousha HI. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma. Tumor Biol. 2014;35:11559–64.CrossRefGoogle Scholar
  34. 34.
    Poon TC, Yip T-T, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem. 2003;49:752–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012;10:428–33.CrossRefPubMedGoogle Scholar
  37. 37.
    Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009;49:1602–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. New Engl J Med. 1993;328:1802–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55:483–90.CrossRefPubMedGoogle Scholar
  41. 41.
    Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol. 2010;52:614–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Shevde L, Das S, Clark D, Samant R. Osteopontin: an effector and an effect of tumor metastasis. Curr Mole Med. 2010;10:71–81.CrossRefGoogle Scholar
  43. 43.
    Singal A, Volk M, Waljee A, Salgia R, Higgins P, Rogers M, Marrero J. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.CrossRefPubMedGoogle Scholar
  44. 44.
    Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003;94:259–62.CrossRefPubMedGoogle Scholar
  45. 45.
    Takikawa Y, Suzuki K, Yamazaki K, Goto T, Madarame T, Miura Y, Yoshida T, Kashiwabara T, Sato S. Plasma abnormal prothrombin (PIVKA-π): a new and reliable marker for the detection of hepatocellular carcinoma. J Gastroenterol Hepatol. 1992;7:1–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Tatarinov I. Detection Of embryo-specific alpha-globulin in the blood serum of a patient with primary liver cancer. Vopr Med Khim. 1963;10:90–1.Google Scholar
  47. 47.
    Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528–36.CrossRefPubMedGoogle Scholar
  48. 48.
    Wan H-G, Xu H, Gu Y-M, Wang H, Xu W, Zu M-H. Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38:706–14.CrossRefPubMedGoogle Scholar
  49. 49.
    Wang M, Mehta A, Block TM, Marrero J, di Bisceglie AM, Devarajan K. A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables. BMC Med Genom. 2013;6:S9.CrossRefGoogle Scholar
  50. 50.
    Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:1417–24.CrossRefPubMedGoogle Scholar
  51. 51.
    Yang J, Li J, Dai W, Wang F, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Zhu R. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp Ther Med. 2015;9:1413–20.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212–20.CrossRefPubMedGoogle Scholar
  53. 53.
    Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19:920–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Molecular and Clinical Cancer MedicineUniversity of LiverpoolLiverpoolUK
  2. 2.The Clatterbridge Cancer Centre NHS Foundation TrustBebingtonUK

Personalised recommendations